Results 151 to 160 of about 438,216 (309)

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen   +10 more
wiley   +1 more source

Impact of In-Office Dispensing Adoption by Urology Practices on Oral Specialty Drug Use in Advanced Prostate Cancer. [PDF]

open access: yesCancer Med
Faraj KS   +8 more
europepmc   +1 more source

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner   +13 more
wiley   +1 more source

ICI-RS 2015 : is a better understanding of sleep the key in managing nocturia? [PDF]

open access: yes, 2018
Cherian, Jerald   +8 more
core   +2 more sources

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel   +21 more
wiley   +1 more source

What’s Up in Urology Journal, Summer 2011?

open access: yesUrology Journal, 2011
Urology Journal
doaj  

Attributes of Society of Genitourinary Reconstructive Surgeons Fellows and Early Career Trajectory of the Recent Graduates [PDF]

open access: yes, 2019
Baradaran, Nima   +6 more
core  

Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer. [PDF]

open access: yesBladder Cancer
Kaufmann E   +48 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy